US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

76.78 -1.75 (-2.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗
This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Four Investor Conferences During November
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized... 
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores. 
Via Benzinga
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Dianthus Therapeutics's Future ↗
 
Via Benzinga
News headline image
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
News headline image
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline ↗
Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results. 
Via Benzinga
News headline image
Top movers in Monday's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Oncology Institute Announces Changes to Board of Directors
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman 
From Toi Management, LLC
Via GlobeNewswire
News headline image
Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates ↗
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026. 
Via Chartmill
< Previous 1 2 3 4 Next >